Pharma News

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for CNS disorders, announced the start of patient enrollment in a first efficacy trial of ND0612H, the company’s continuously administered subcutaneous levodopa/carbidopa solution. This treatment is intended to be an alternative to current treatments for patients with advanced Parkinson’s disease that require surgical intervention.

The world's largest database for cancer drug discovery has been updated by adding three-dimensional structures of faulty proteins and maps of cancer's communication networks, reports a study.

Leading private healthcare provider in Kerala KIMS Hospital, headquartered here, on Monday announced the launch of the first genetic disease identification centre in collaboration with Medgenome, India.

Researchers have found a potential new treatment for diabetes in an anti-body that they developed to target a hormone in adipose or fat tissue.

[adsense:336x280:8701650588]

Using gold nanoparticles, South Korean scientists have created an ultra-thin and stretchable wearable device that can provide continuous heart rate monitoring.

Teenagers who experience their first sexual intercourse at an early age run a greater risk of contracting sexually transmitted infections (STIs) which includes diseases such as gonorrhea, syphilis, chlamydia, HIV or other infection, warns a study.

In the first study of its kind, researchers have identified a dozen inherited traits related to sleep, awake and activity cycles that are associated with severe bipolar disorder.

A person's diet can greatly impact his sperm's quality leading to harmful gene mutation in his children, scientists including an Indian-origin researcher have discovered.

Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for GBT440 for the treatment of patients with sickle cell disease (SCD). GBT440 is being developed as a potentially disease-modifying therapy for SCD.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies to treat CNS disorders, announced that the US Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for MIN-101, a first-in-class 5-HT2a and sigma2 antagonist in clinical development for the treatment of schizophrenia.